Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02511106 · ClinicalTrials.gov registry record · Phase 3
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
A Phase 3 study of Stage IB-IIIA Non-small Cell Lung Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 682
- Enrollment target
- 20
- Study locations
NCT02511106 is a Phase 3 study of Stage IB-IIIA Non-small Cell Lung Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 682 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT02511106, a Phase 3 study of Stage IB-IIIA Non-small Cell Lung Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 682 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy
Conditions Studied
Interventions
- DRUG AZD9291 80 mg/40 mg
- DRUG Placebo AZD9291 80 mg/40 mg
- DRUG Open-label AZD9291 80 mg/40 mg
Study Locations (20)
California
- Research Site - Los Angeles
- Research Site - Santa Monica
- Research Site - Santa Rosa
- Research Site - Torrance
Florida
- Research Site - Fort Myers
- Research Site - Pembroke Pines
- Research Site - St. Petersburg
Connecticut
- Research Site - New Haven
- Research Site - Norwalk
Illinois
- Research Site - Chicago
- Research Site - Elk Grove Village
New Jersey
- Research Site - Brick
- Research Site - Florham Park
Colorado
- Research Site - Grand Junction
Georgia
- Research Site - Athens
Hawaii
- Research Site - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2015-10-21 |
| Est. Completion | 2029-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02511106
The ClinicalTrials.gov registry entry for NCT02511106 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 682 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage IB-IIIA Non-small Cell Lung Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which AZD9291 80 mg/40 mg is the first listed.
NCT02511106 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02511106 about?
NCT02511106 is a clinical study titled "AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.". To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy
What is the current status of trial NCT02511106?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 682 participants. The study started on 2015-10-21. Estimated completion is 2029-01-31.
What conditions does trial NCT02511106 study?
This clinical trial studies the following conditions: Stage IB-IIIA Non-small Cell Lung Carcinoma.
What interventions are being tested in trial NCT02511106?
The interventions under investigation include: AZD9291 80 mg/40 mg (DRUG), Placebo AZD9291 80 mg/40 mg (DRUG), Open-label AZD9291 80 mg/40 mg (DRUG).
Who is sponsoring clinical trial NCT02511106?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02511106 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.